

Cochrane Canada: Bringing 'Living Systematic Reviews' To Life Workshop, May 2017

## **Enabling technologies for Living Systematic Reviews**

State of the Science

Ian Shemilt, EPPI-Centre, University College London, UK











Elliott JH, Turner T, Clavisi O, Thomas J et al. (2014). PLoS Medicine 11 (2): e1001603



















Through a combination of human and machine effort the aim is to identify and classify ALL trials using this system.


Identifying studies for LSRs\* will then be a simple process of specifying the relevant PICO alert

\* For RCTs





## Demo – PICOFinder



https://uat-data.cochrane.org/pico-finder





## Automation tools for LSR workflows

## **Study Identification**


- Electronic search development
- Selecting studies (title-abstract &full-text screening)
  - Active learning (prospective)
  - ML classifiers (e.g. RCT classifier)
- Mapping research activity

#### Data Extraction

- Risk of bias assessment
- Other study characteristics (e.g. PICO)
- Statistical outcome data

### Synthesis and Sense-making

- Automated text generation (e.g. RevMAN HAL)
- Automated meta-analysis?
- Dynamic updating of iSoF tables?





## **Evidence Pipeline**

Finding and classifying relevant research


















# Demo – RCT Classifer EPPI Reviewer

the model is applied to new it trained on more than 280,00 (This function enables you to	0 records screened by the Cochran- build a linear classifier from a bag		entatio	n of your studie	es, using th	e scikit-le	earn python lib	rary.)
Stage 1: build the model	Stage 2: ap	Stage 2: apply the model				C Refresh model list		
Learn to apply this code	•	Title	7	Applies	Compa	red wi 🏹	Precision \(	Recall
Distinguish from this code	•							
Name for your model	Edit title	1						
	Build model							
	O Apply ab	Apply above selected model     Appl				pply to all items in review		
(Go straight to stage 2 if you are applying the RCT model.)		Apply R0	T mod	iel		Apply to it	tems with this	code
(Go straight to stage 2 if you	are applying the Rel modelly		O Apply systematic review model					
(Go straight to stage 2 if you	are applying the Rel modelly	O Apply sy	stemat	tic review mode	el .			
(Go straight to stage 2 if you	are applying the net modelly			tic review mode		Apply to it	tems from this	source

https://eppi.ioe.ac.uk/cms/er4/





## Automation tools in LSR workflows

## **Study Identification**

- Electronic search development
- Selecting studies (title-abstract &full-text screening)
  - Active learning (prospective)
  - ML classifiers (e.g. RCT classifier)
- Mapping research activity

#### **Data Extraction**

- Risk of bias assessment
- Other study characteristics (e.g. PICO)
- Statistical outcome data

#### Synthesis and Sense-making

- Automated text generation (e.g. RevMAN HAL)
- Automated meta-analysis?
- Dynamic updating of iSoF tables?

Increasing interest and evaluation activity





## Data extraction

- RobotReviewer can identify phrases relating to study PICO characteristics and risk of bias
- ExaCT extracts trial characteristics (e.g. eligibility criteria)
- Systematic review found that no unified framework yet exists
- More evaluative work is needed on larger datasets
- Further challenges include extraction of data from tables and graphs




of automatically extracting data elements from full texts has not been

systematic review of published and unpublished methods to automate data extraction f

Methods: We systematically searched PubMed, IEEEXplore, and ACM Digital Library to identify potentially rele



## Demo – RobotReviewer



https://robot-reviewer.vortext.systems/





## Automation tools in LSR workflows

## **Study Identification**

- Electronic search development
- Selecting studies (title-abstract &full-text screening)
  - Active learning (prospective)
  - ML classifiers (e.g. RCT classifier)
- Mapping research activity

#### **Data Extraction**

- Risk of bias assessment
- Other study characteristics (e.g. PICO)
- Statistical outcome data

#### Synthesis and Sense-making

- Automated text generation (e.g. RevMAN HAL)
- Automated meta-analysis?
- Dynamically updated iSoF tables?

Increasing interest and evaluation activity





Cochrane Canada: Bringing 'Living Systematic Reviews' To Life Workshop, May 2017

## **Enabling technologies for Living Systematic Reviews**

State of the Science

Ian Shemilt, EPPI-Centre, University College London, UK







# Demo – RCT Classifer EPPI Reviewer

the model is applied to new it trained on more than 280,00 (This function enables you to	0 records screened by the Cochran- build a linear classifier from a bag		entatio	n of your studie	es, using th	e scikit-le	earn python lib	rary.)
Stage 1: build the model	Stage 2: ap	Stage 2: apply the model				C Refresh model list		
Learn to apply this code	•	Title	7	Applies	Compa	red wi 🏹	Precision \(	Recall
Distinguish from this code	•							
Name for your model	Edit title	1						
	Build model							
	O Apply ab	Apply above selected model     Appl				pply to all items in review		
(Go straight to stage 2 if you are applying the RCT model.)		Apply R0	T mod	iel		Apply to it	tems with this	code
(Go straight to stage 2 if you	are applying the Rel modelly		O Apply systematic review model					
(Go straight to stage 2 if you	are applying the Rel modelly	O Apply sy	stemat	tic review mode	el .			
(Go straight to stage 2 if you	are applying the net modelly			tic review mode		Apply to it	tems from this	source

https://eppi.ioe.ac.uk/cms/er4/



## Institute of Education



Search History (19)								
	# 🛦	Searches	Results					
	1	statin.ti,ab.	27765					
	2	'crossover procedure'.de.	50347					
	3	'double-blind procedure'.de.	133958					
	4	'randomized controlled trial'.de.	439304					
	5	'single-blind procedure'.de.	26234					
	6	random*.de,ab,ti.	1336088					
	7	factorial*.de,ab,ti.	56920					
	8	crossover*.de,ab,ti.	80010					
	9	(cross adj1 over*).de,ab,ti.	26114					
	10	placebo*.de,ab,ti.	375736					
	11	(doubl* adj1 blind*).de,ab,ti.	169392					
	12	(singl* adj1 blind*).de,ab,ti.	19729					
	13	assign*.de,ab,ti.	301872					
	14	allocat*.de,ab,ti.	111271					
	15	volunteer*.de,ab,ti.	217571					
	16	or/2-5	494578					
	17	or/6-16	1995817					
	18	16 or 17	1995817					
	19	1 and 18	8379					

'Statin' and 'RCT' [filter]



#### Institute of Education



```
RCT-Statin.txt
   - 364701077
   - Aalbers, J.
   - April
  - Embase
DB
   - Ovid Technologies
  - 3
PY - 2012
SP
ST - Coenzyme Q10, an anti-oxidant of value to reduce oxidative stress; also useful to reduce
statin-induced myalgia
T2 - Cardiovascular Journal of Africa
TI - Coenzyme Q10, an anti-oxidant of value to reduce oxidative stress; also useful to reduce
statin-induced myalgia
UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed14&AN=364701077
http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:
22555643&id=doi:&issn=1995-1892&isbn=&volume=23&issue=3&spage=170&pages=170&date=2012&title=Ca
rdiovascular+Journal+of+Africa&atitle=Coenzyme+Q10%2C+an+anti-
oxidant+of+value+to+reduce+oxidative+stress%3B+also+useful+to+reduce+statin-
induced+myalgia&aulast=Aalbers
VL - 23
ID - 3582
ER -
AB - Although statins have been shown to prevent contrast-induced acute kidney injury in
patients with acute coronary syndromes, the benefit of statins is not known for patients at
high risk for nephropathy who undergo elective coronary angiography. Two hundred twenty
consecutive statin-naive patients with chronic kidney disease (estimated glomerular filtration
rate <60 ml/min/1.73 m<sup>2</sup>) who underwent elective coronary or peripheral angiography
were randomly assigned to receive rosuvastatin (40 mg on admission, followed by 20 mg/day; n =
110) or no statin treatment (control group, n = 110). Contrast-induced acute kidney injury was
defined by an absolute increase in serum creatinine of >0.5 mg/dl or a relative increase of
>25% measured 48 or 72 hours after the procedure. Contrast-induced acute kidney injury
occurred in 15 patients (7.2%), 9 (8.5%) in the control group and 6 (5.8%) in the rosuvastatin
group (p = 0.44). The incidences of adverse cardiovascular and renal events (death, dialysis,
myocardial infarction, stroke, or persistent renal damage) were similar between the two groups
at follow-up. In conclusion, rosuvastatin did not reduce the risk for contrast-induced acute
kidney injury or other clinically relevant outcomes in at-risk patients who underwent coronary
and peripheral vascular angiography. Copyright © 2015 Elsevier Inc.
AD - (Abaci, Arat Ozkan, Kocas, Cetinkal, Sukru Karaca, Baydar, Gurmen) Department of
Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey (Kaya) Department of
Biochemistry, Istanbul University Cardiology Institute, Istanbul, Turkey
   - 602076036
   - Abaci, O.
   - Arat Ozkan, A.
   - Kocas, C.
   - Cetinkal, G.
   - Sukru Karaca, O.
  - Baydar, O.
   - Kaya, A.
   - Gurmen, T.
   - 01 Apr
   - Embase
DP - Ovid Technologies
```

- > Import to EndNote
- > RefMan (RIS) Export (.txt)






Add/Manage Source(s)									
9	Import New PubMed Import					Used Sources List			
Import Filter:	RIS •	Name:	RCT-Statin.txt		Read File	Name 🗸			
Search String:	Search String: Description								
	Date of Search: 5/11/17								
√ Title					<u> </u>				
14 Coenzyme	Q10, an anti-oxidant of value to reduce oxidative stress; also useful to	reduce stati	n-induced myalgia						
14 Impact of	14 Impact of Rosuvastatin on Contrast-Induced Acute Kidney Injury in Patients at High Risk for Nephropathy Undergoing Elective Angiography								
14 Clinician's	14 Clinician's use of the Statin Choice decision aid in patients with diabetes: A videographic study nested in a randomized trial								
14 Rosuvasta	tin and atorvastatin: Comparative effects on glucose metabolism in nor	-diabetic pat	ients with dyslipidaemia						
14 Simvastat	14 Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlle								
14 Statin-ind	14 Statin-induced myopathy: A review and update								
14 Effects of	modifying triglycerides and triglyceride-rich lipoproteins on cardiovascu	ar outcomes							
14 Associatio	14 Association of statins and beta blockers with pre-operative CRP levels in non cardiac surgery patients								
14 A review o	14 A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis								
14 Statins: P	14 Statins: Practical considerations - A review								
14 High seru	14 High serum Abeta and vascular risk factors in first-degree relatives of alzheimer's disease patients								
14 A trial of F	14 A trial of Pitavastatin versus Rosuvastatin for Dyslipidemia in chronic kidney disease								
14 Pharmaco	14 Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108								
14 Neutral ef	fects of pitavastatin 4 mg and pravastatin 40 mg on blood glucose and	HbA <inf>1c&lt;</inf>	:/inf> levels over 12 weeks: Pres	specified safety and	alysis fror				
1					•				
8379 items fo	und.		Include? 🗸 Upload Items	Safe Upload (slow	):				
atus: Normal. Last code update: 09/05/2017   User: Ian Shemilt   Review: Statin - RCT Classifier Demo									

> Import to EPPI Reviewer







> Create code > Assign items to code

